Clinical Trials Browser

Phase 1 × Rifaximin × Tumor-Agnostic × Clear all

NCT00967096 2013-11-27

Rifaximin for Preventing Acute Graft Versus Host Disease (AGVHD)

Phase 1 Completed

Neoplasms